CTLA4 and neoplasm: Importantly, the ability of NIR-PIT to induce ICD provides a strong rationale for combination with immune checkpoint inhibitors such as anti-PD-1/PD-L1 or anti-CTLA-4 antibodies, which may enhance and prolong anti-tumor responses in ovarian cancer.19